Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Preprint |
| Published: |
2025
|
| Subjects: | |
| Online Access: | https://arxiv.org/abs/2503.11068 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866917964373032960 |
|---|---|
| author | Lin, Leqi Zhou, Xingyu Yang, Kaiyuan Chen, Xizhong |
| author_facet | Lin, Leqi Zhou, Xingyu Yang, Kaiyuan Chen, Xizhong |
| contents | Pharmaceutical process design and development for generic, innovative, or personalized drugs have always been a time-consuming, costly, rigorous process, that involves multi-stage evaluation for better quality control and assurance. Large language models (LLMs), a type of generative artificial intelligence system, can augment laboratory research in the pharmaceutical engineering process by helping scientists to extract knowledge from literature, design parameters, and collect and interpret experimental data ultimately accelerating scientific discovery. LLMs with prompt engineering technologies change the researchers thinking protocol from traditional empirical knowledge to streamlined thinking that connects the performance and structured parameters together. In this work, we investigate and evaluate how prompt engineering technologies can enhance the drug design process from different strategies such as zero-shot, few-shot, chain-of-thought, etc. The dissolution profile for specific drugs is predicted and suggested from the LLMs model. Furthermore, the fundamental physical properties such as PSD, aspect ratio, and specific surface area could be inversely designed from the LLMs model. Finally, all the results are evaluated and validated by real-world cases to prove the reliability of prompt engineering techniques. Initial evaluations show an MSE of 23.61 and R2 of 0.97 in zero-shot, an MSE of 114.89 and R2 of 0.90 in zero-shot-CoT, an MSE of 57.0 and R2 of 0.92 in few-shot, a MSE of 22.56 and R2 of 0.97 in few-shot-CoT and a MSE of 10.56 and R2 of 0.99 with the involvement of RAG. This work breaks down any barriers in developing a systematic framework where LLMs assist in formulation design, process control, and decision-making. Finally, we conclude the work by discussing open challenges and future research directions in pharmaceutical processes. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2503_11068 |
| institution | arXiv |
| publishDate | 2025 |
| record_format | arxiv |
| spellingShingle | DeepSeek Powered Solid Dosage Formulation Design and Development Lin, Leqi Zhou, Xingyu Yang, Kaiyuan Chen, Xizhong Emerging Technologies Pharmaceutical process design and development for generic, innovative, or personalized drugs have always been a time-consuming, costly, rigorous process, that involves multi-stage evaluation for better quality control and assurance. Large language models (LLMs), a type of generative artificial intelligence system, can augment laboratory research in the pharmaceutical engineering process by helping scientists to extract knowledge from literature, design parameters, and collect and interpret experimental data ultimately accelerating scientific discovery. LLMs with prompt engineering technologies change the researchers thinking protocol from traditional empirical knowledge to streamlined thinking that connects the performance and structured parameters together. In this work, we investigate and evaluate how prompt engineering technologies can enhance the drug design process from different strategies such as zero-shot, few-shot, chain-of-thought, etc. The dissolution profile for specific drugs is predicted and suggested from the LLMs model. Furthermore, the fundamental physical properties such as PSD, aspect ratio, and specific surface area could be inversely designed from the LLMs model. Finally, all the results are evaluated and validated by real-world cases to prove the reliability of prompt engineering techniques. Initial evaluations show an MSE of 23.61 and R2 of 0.97 in zero-shot, an MSE of 114.89 and R2 of 0.90 in zero-shot-CoT, an MSE of 57.0 and R2 of 0.92 in few-shot, a MSE of 22.56 and R2 of 0.97 in few-shot-CoT and a MSE of 10.56 and R2 of 0.99 with the involvement of RAG. This work breaks down any barriers in developing a systematic framework where LLMs assist in formulation design, process control, and decision-making. Finally, we conclude the work by discussing open challenges and future research directions in pharmaceutical processes. |
| title | DeepSeek Powered Solid Dosage Formulation Design and Development |
| topic | Emerging Technologies |
| url | https://arxiv.org/abs/2503.11068 |